CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Net product sales	$ 857,468	$ 737,562	$ 2,475,869	$ 1,939,954
Sanofi collaboration revenue	144,392	224,735	527,500	593,201
Bayer Collaboration Revenue	191,298	157,596	562,786	415,679
Other revenue	26,964	17,529	67,445	56,817
Total revenues	1,220,122	1,137,422	3,633,600	3,005,651
Expenses:
Research and development	543,047	425,924	1,573,089	1,159,367
Selling, general, and administrative	270,045	209,993	851,760	543,572
Cost of goods sold	29,901	67,199	150,090	170,624
Cost of collaboration and contract manufacturing	14,327	41,884	74,923	111,254
Total expenses	857,320	745,000	2,649,862	1,984,817
Income from operations	362,802	392,422	983,738	1,020,834
Other income (expense):
Investment income	3,301	2,140	8,351	3,973
Interest and other expense, net	(222)	(1,273)	(3,801)	(26,999)
Nonoperating Income (Expense)	3,079	867	4,550	(23,026)
Income before income taxes	365,881	393,289	988,288	997,808
Income tax expense	(101,077)	(182,891)	(345,881)	(516,746)
Net income	$ 264,804	$ 210,398	$ 642,407	$ 481,062
Net income per share - basic	$ 2.53	$ 2.04	$ 6.14	$ 4.68
Net income per share - diluted	$ 2.27	$ 1.82	$ 5.51	$ 4.18
Weighted average shares outstanding - basic	104,833	103,348	104,586	102,825
Weighted average shares outstanding - diluted	116,466	115,944	116,567	115,144
Statements of Comprehensive Income
Net income	$ 264,804	$ 210,398	$ 642,407	$ 481,062
Other comprehensive income (loss):
Unrealized loss on marketable securities, net of tax	(8,103)	(11,432)	(11,471)	(44,530)
Comprehensive income	$ 256,701	$ 198,966	$ 630,936	$ 436,532